title: Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany.
abstract: The introduction of routine infant vaccination against pneumococcal disease has resulted in a decreased overall invasive pneumococcal disease incidence in adults but also a change in invasive pneumococcal disease serotypes. This study aimed to assess the cost-effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany in this context. A population-based Markov model was developed. A cohort of adults currently eligible for vaccination was followed until death. Adult vaccination with PPV23 was associated with an incremental cost-effectiveness ratio of €17,065/quality-adjusted life years gained from the third-party payer's perspective. Univariate sensitivity analyses showed that the incremental cost-effectiveness ratio was below €50,000/quality-adjusted life years gained in most test scenarios. The model suggests that adult PPV23 vaccination is cost effective in Germany, due to its broad serotype coverage. This is despite epidemiological changes in Streptococcus pneumoniae serotypes caused by wider use of pneumococcal conjugate vaccines during childhood.
authors.affiliation: Amaris, 1 Water Lane, London NW1 8NZ, UK. yjiang@amaris.com
authors.forename: Yiling
authors.initials: Y
authors.lastname: Jiang
authors.forename: Aline
authors.initials: A
authors.lastname: Gauthier
authors.forename: Lieven
authors.initials: L
authors.lastname: Annemans
authors.forename: Mark
authors.initials: M
authors.lastname: van der Linden
authors.forename: Laurence
authors.initials: L
authors.lastname: Nicolas-Spony
authors.forename: Xavier
authors.initials: X
authors.lastname: Bresse
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008390:Markov Chains; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000191:economics; D011018:Pneumonia, Pneumococcal / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D019057:Quality-Adjusted Life Years; D013296:Streptococcus pneumoniae / Q000302:isolation & purification; D055815:Young Adult
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines